Zöldhályog (glaukóma): ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• VEGF 1
• NRF2 0
• PI3K 0
• STAT3 0
• AMPK 0
• MAPK 0
• AKT 0
• GLP-1 1
• NLRP3 0
• STING 0
• TNF 0
• IL-1 0
• JAK 0
• MMP-9 1
• PPAR 0
• SIRT1 0
• TP53 0
• ACE2 0
• GPX4 0
• IL-6 1
• mTOR 0
• YAP 0
• APOE 0
• BDNF 0
• CD38 0
• CGRP 0
• COX-2 0
• ERK 0
• GIP 0
• HSP90 0
• IL-17 0
• MEK 0
• MYCN 0
• NF1 0
• NMDA 0
• PDGFR 0
• RANKL 0
• RB1 0
• TIM-3 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Next-generation therapeutics for vascular diseases (TIE2gether)

  Helsingin Yliopisto· Helsinki, Finnország· EU contribution 4 273 568 EUR· until 2031. jan.· 7 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Tailored lipid nanoparticles for iontophoretic ocular drug delivery. (ODiN)

  Universita Degli Studi di Parma· Parma, Olaszország· EU contribution 193 643 EUR· until 2029. jan.· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  Peptidomimetic therapy to promote central Nervous System repair (POPEYE)

  Institut National de la Sante Et de la Recherche Medicale· Paris, Franciaország· EU contribution 150 000 EUR· until 2027. jún.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-ERC

  Pharmacological and gene therapy targeting of NMNAT2 for neuroprotection in glaucoma (TARGET-NMNAT2)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 2 261 875 EUR· until 2030. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Nanoparticle-mediated ocular delivery of novel NAD-boosting small molecules for ophthalmic disease. (NanoNAD)

  Karolinska Institutet· Stockholm, Svédország· EU contribution 252 180 EUR· until 2027. márc.

• European Commission (Horizon Europe) · HORIZON-ERC

  Visual Impairment Screening using Images from Ophthalmology and Novel pathways for Structural Analysis and Fast Evaluation (VISIONSAFE)

  Universidad de Zaragoza· Zaragoza, Spanyolország· EU contribution 1 497 873 EUR· until 2030. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN-JD

  European Glaucoma Research Training program - Advancing the Approach of Advanced glaucoma (EGRET-AAA)

  Academisch Ziekenhuis Groningen· Groningen, Hollandia· EU contribution 4 116 902 EUR· until 2027. dec.· 6 countries

• European Commission (Horizon 2020) · ERC-STG

  Retina Organoid Mechanobiology (ROMB)

  Universitaet Ulm· Ulm, Németország· EU contribution 1 497 175 EUR· until 2026. dec.

  The disease is named only in the funder's project summary, not in the title.

8 of 8 running projects, newest first. Listed amounts together: 14,2 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 8
• Organoids 2
• Mendelian Randomization Analysis 24
• CRISPR-Cas Systems 3
• Gene Expression Profiling 15
• Sequence Analysis, RNA 1
• Exome Sequencing 16
• Proteomics 21
• Metabolomics 11
• Mass Spectrometry 4
• Flow Cytometry 7
• Immunohistochemistry 17
• Magnetic Resonance Imaging 22
• Machine Learning 27
• Deep Learning 35
• Cohort Studies 24
• Genome-Wide Association Study 29

• The Heterogeneity of the Neurovascular Unit in the Optic Nerve Head During Glaucomatous Neurodegeneration Based on Single-Cell RNA Sequencing.

  FASEB J, 2026. okt.

• Single-Cell atlas of aqueous humor outflow in glaucomatous Non-Human Primates identified MGP as a regulator of ECM remodeling.

  Exp Eye Res, 2026. aug.

• Single-cell characterization of anterior segment development in the mouse reveals the cell types, pathways, and signals driving formation of the trabecular meshwork and Schlemm's canal.

  Elife, 2026. júl.

• Lactylation-Associated Immune Metabolic Reprogramming Identifies S100A2 and S100A14 as Candidate Diagnostic Biomarkers in Primary Open-Angle Glaucoma: An Integrated Bulk and Single-Cell Transcriptomic Analysis.

  Genes (Basel), 2026. márc.

• Single-cell profiling of trabecular meshwork identifies mitochondrial dysfunction in a glaucoma model that is protected by vitamin B3 treatment.

  Elife, 2026. jan.

• Revealing the role of regulatory microglial IRF7-NLRP3 interactions in optic nerve damage of normal-tension glaucoma based on single-cell RNA sequencing.

  Front Immunol, 2026. jan.

• Two-color fluorescence scanning laser ophthalmoscopy for in vivo mouse retinal ganglion cell imaging at the single-cell level.

  Appl Opt, 2026. jan.

• Single-Cell Transcriptome Analysis of the Retina During the Development of Normal Tension Glaucoma in Mice.

  Inflammation, 2025. dec.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.